Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Special Issues

This review will provide the oncology care team with information on the latest research developments and insights into best practices in treating multiple myeloma to enhance their management of patients with this disease, leading to an improvement in clinical outcomes.
This review will provide the oncology care team with information on the latest research developments and insights into best practices in the use of biosimilars to enhance their management of patients with cancer, leading to an improvement in clinical outcomes.
This review will provide the oncology care team with information on the latest research developments and insights into best practices in treating ovarian cancer to enhance their management of patients with this disease, leading to an improvement in clinical outcomes.
Epithelial ovarian cancer is the fifth leading cause of cancer mortality in women and is the leading cause of death due to gynecologic cancer in the United States.

There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.

Ovarian cancer is the most lethal gynecologic cancer and the fifth leading cause of cancer death among women in the United States.1 No effective screening tests are available, and more than 70% of patients are diagnosed with advanced-stage disease.2

The Lynx Group is pleased to bring you the Third Annual Oncology Guide to New FDA Approvals. The goal of this Guide is to offer oncologists, pharmacists, oncology nurses, and other healthcare stakeholders a comprehensive overview of new hematology oncology drugs approved by the US Food and Drug Administration (FDA) in 2017. This practical tool offers a quick, yet detailed, evidence-based resource for oncology providers to guide their management of patients with cancer.
In 2017, the US Food and Drug Administration (FDA) approved 46 new drugs, a 21-year high. In addition to these impressive approvals, the first-ever 3 gene therapies were also approved. FDA Commissioner Scott Gottlieb, MD, noted that these approvals represent “a whole new scientific paradigm for the treatment of serious diseases.”
The cancer drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories.

The FDA accelerated the approval of brigatinib (Alunbrig), a new generation of oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib..

Page 1 of 3
Results 1 - 10 of 24